28 April 2023
SHARE NOW
Cell Therapy
Scaling Up
Viral/Non-Viral Vectors
Katja Betts, CEO at PROGEN, discusses the core issues affecting biotechs working with AAV and how these could be addressed at both the individual team and industry-wide levels.
Katja begins by introducing the challenges facing biotechs within AAV, and explores the possibility for devising standards for the field. Katja continues to explore challenges that occur when scaling up AAV operations, before sharing her top tips for developing AAV.
Finally, Katja discusses her AAV ‘headline highlights’ from the past year or so, and suggests what we might be able to expect from the next 5 years.
This interview has been produced in partnership with PROGEN and was recorded at Advanced Therapies Week 2023.
More like this
20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry
Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.
4 December 2023
Oxford Biomedica Acquires ABL Europe from Institut Mérieux
Oxford Biomedica Acquires ABL Europe from Institut Mérieux
6 December 2023
Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome
Two female pediatric patients with Rett syndrome were the first children worldwide to receive the promising treatment with Neurogene’s lead gene therapy product.
5 December 2023
Discover more like this
